Phase I Trial of Sunitinib Malate plus Interferon-α for Patients with Metastatic Renal Cell Carcinoma

BACKGROUND: Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor that has demonstrated superior efficacy over interferon (IFN)–α in a phase III trial in first-line, metastatic renal cell carcinoma (RCC). Herein, we report the results of a phase I dose-finding study of sunitinib in co...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Motzer, Robert J., Hudes, Gary, Wilding, George, Schwartz, Lawrence H., Hariharan, Subramanian, Kempin, Susan, Fayyad, Rana, Figlin, Robert A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394091/
https://ncbi.nlm.nih.gov/pubmed/19213665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CGC.2009.n.005
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky